Organ preservation trials for laryngeal cancer

Otolaryngologic Clinics of North America

Volumn 35, Issue 5, 2002, Pages 1035-1054

  Gilbert, Jill ^a   Forastiere, Arlene A ^b,c  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; HYDROXYUREA; PACLITAXEL;

ADVANCED CANCER; CANCER CONTROL; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; LARYNX CANCER; LARYNX CARCINOMA; MUCOSA INFLAMMATION; ORGAN PRESERVATION; RADIOSENSITIZATION; REVIEW; SEPSIS; SQUAMOUS CELL CARCINOMA; TREATMENT INDICATION; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; FLUOROURACIL; HUMANS; LARYNGEAL NEOPLASMS; NEOPLASMS, SQUAMOUS CELL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS;

EID: 0036813036     PISSN: 00306665     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0030-6665(02)00035-X     Document Type: Review

References (81)

1. DeSanto LW, Olsen KD, Perry WC, et al. Quality of life after surgical treatment of cancer of the larynx. Ann Otol Rhinol Laryngol 1995;104:763-9.
2. Mendenhall WM, Parsons JT, Mancuso AA, et al. Definitive radiotherapy for T3 squamous cell carcinoma of the glottic larynx. J Clin Oncol 1997;15:2394-402.
3. Bataini P, Brugere J, Bernier J, et al. Results of a radical radiotherapeutic treatment of carcinoma of the pyriform sinus: Experience of the Institute Curie. Int J Radiat Oncol Biol Phys 1982;8:1277-86.
4. Castelijns J, Golding R, van Schaik C, et al. MR findings of cartilage invasion by laryngeal cancer: Value in predicting outcome of radiation therapy. Radiology 1990;174:669-73.
5. Fletcher G, Jesse R, Lindberg R, et al. The place of radiotherapy in the management of the squamous cell carcinoma of the supraglottic larynx. American Journal of Roentgenology, Radium Therapy, and Nuclear Medicine 1970;108:19-26.
6. Harwood A, Beale F, Cummings B, et al. T4N0M0 glottic cancer: All analysis of dose-time volume factors. Int J Radiat Oncol Biol Phys 1981;7:1507-12.
7. Isaacs J, Mancuso A, Mendenhall W, et al. Deep spread patterns on CT staging of T2-4 squamous cell laryngeal carcinoma. Otolaryngol Head Neck Surg 1988;99:455-64.
8. Mendenhall W. T3-4 squamous cell carcinoma of the larynx treated with radiation therapy alone. Semin Radiat Oncol 1998;8:262-9.
9. Pameijer F, Mancuso A, Mendenhall W, et al. Can pretreatment computed tomography predict local control in T3 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy? Int J Radiat Oncol Biol Phys 1997;37:1011-21.
10. Parsons J, Mendenhall W, Stringer S, et al. T4 laryngeal carcinoma: Radiotherapy alone with surgery reserved for salvage. Int J Radiat Oncol Biol Phys 1998;40:549-52.
11. Wang C, Montgomery W. Deciding on optimal management of supraglottic carcinoma. Oncology (Huntingt) 1991;5:41-6.
12. Garden AS. Altered fractionation for head and neck cancer. Oncology (Huntingt) 2001; 15:1326-32.
13. Horiot JC, Le Fur R, N'Guyen T, et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: Final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 1992;25:231-41.
14. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7-16.
15. Lee WR, Berkey B, Marcial V, et al. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: A secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys 1998;42:1069-75.
16. Nguyen-Tan PF, Le QT, Quivey JM, et al. Treatment results and prognostic factors of advanced T3-4 laryngeal carcinoma: The University of California, San Francisco (UCSF) and Stanford University Hospital (SUH) experience. Int J Radiat Oncol Biol Phys 2001; 50:1172-80.
17. Athanasiadis I, Taylor 4th S, Vokes EE, et al. Phase II study of induction and adjuvant chemotherapy for squamous cell carcinoma of the head and neck. A long-term analysis for the Illinois Cancer Center. Cancer 1997;79:588-94.
18. Rooney M, Kish J, Jacobs J, et al. Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer 1985;55:1123-8.
19. Toohill RJ, Anderson T, Byhardt RW, et al. Cisplatin and fluorouracil as neoadjuvant therapy in head and neck cancer. A preliminary report. Arch Otolaryngol Head Neck Surg 1987;113:758-61.
20. Pfister D, Strong E, Harrison L, et al. Larynx preservation with combined chemotherapy and radiation therapy in advanced but resectable head and neck cancer. J Clin Oncol 1991;9:850-9.
21. Demard F, Chauvel P, Santini J, et al. Response to chemotherapy as justification for modification of the therapeutic strategy for pharyngolaryngeal carcinomas. Cancer 1990; 12:225-31.
22. Clayman G, Weber R, Guillamondegui O, et al. Laryngeal preservation for advanced laryngeal and hypopharyngeal cancers. Arch Otolaryngol Head Neck Surg 1995;121: 219-23.
23. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991;324:1685-90.
24. Hillman RE, Walsh MJ, Wolf GT, et al. Functional outcomes following treatment for advanced laryngeal cancerPart I-voice preservation in advanced laryngeal cancer. Part II - Laryngectomy rehabilitation: The state of the art in the VA system. Research Speech-Language Pathologists. Department of Veterans Affairs Laryngeal Cancer Study Group. Ann Otol Rhinol Laryngol Suppl 1998;172:1-27.
25. Mohide EA, Archibald SD, Tew M, et al. Postlaryngectomy quality-of-life dimensions identified by patients and health care professionals. Am J Surg 1992;164:619-22.
26. Terrell JE, Fisher SG, Wolf GT. Long-term quality of life after treatment of laryngeal cancer. The Veterans Affairs Laryngeal Cancer Study Group. Arch Otolaryngol Head Neck Surg 1998;124:964-71.
27. Lefebvre JL, Chevalier D, Luboinski B, et al. Larynx preservation in pyriform sinus cancer: Preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996;88:890-9.
28. Adelstein DJ. Induction chemotherapy in head and neck cancer. Hematol Oncol Clin North Am 1999;13:689-98.
29. Hussain M, Salwen W, Kucuk O, et al. Paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: A preliminary report. Semin Oncol 1997;24:S19-45.
30. Forastiere AA, Shank D, Neuberg D, et al. Final report of a phase II evaluation of paclitaxel in advanced squamous cell carcinoma of the head and neck: An Eastern Cooperative Oncology Group Trial (PA 390). Cancer 1998;82(11):2270-4.
31. Hitt R, Paz-Ares L, Hidalgo M, et al. Phase I/II study of paclitaxel/cisplatin as first-line therapy for locally advanced head and neck cancer. Semin Oncol 1997;24:S19-24.
32. Dunphy FR, Dunleavy TL, Harrison BR, et al. Induction paclitaxel and carboplatin for patients with head and neck carcinoma. Analysis of 62 patients treated between 1994 and 1999. Cancer 2001;91:940-8.
33. Janinis J, Papadakou M, Panagos G, et al. Sequential chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced head and neck cancer. Am J Clin Oncol 2001;24:227-31.
34. Cooper JS, Pajak TF, Forastiere A, et al. Precisely defining high-risk operable head and neck tumors based on RTOG #85-03 and #88-24: Targets for postoperative radiochemotherapy? Head Neck 1998;20:588-94.
35. Al-Sarraf M, Pajak TF, Byhardt RW, et al. Postoperative radiotherapy with concurrent cisplatin appears to improve locoregional control for advanced, resectable head and neck cancers: RTOG 88-24. Int J Radiat Oncol Biol Phys 1997;82:777-82.
36. Schmidt-Ullrich RK, Contessa JN, Dent P, et al. Molecular mechanisms of radiation-induced accelerated repopulation. Radiat Oncol Investig 1999;7(6):321-30.
37. Koch WM, Brennan JA, Zahurak M, et al. P53 mutation and locoregional treatment failure in head and neck squamous cell cardinoma. J Natl Cancer Inst 1996;88(21): 1580-6.
38. Rosen EM, Fan S, Rockwell S. The molecular and cellular basis of radiosensitivity: Implications for understanding how normal tissues and tumors respond to therapeutic radiation. Cancer Invest 1999;17(1):56-72.
39. Haffty BG, Son YH, Sasaki CT, et al. Mitomycin C as an adjunct to postoperative radiation therapy in squamous cell carcinoma of the head and neck: Results from two randomized clinical trials. Int J Radiat Oncol Biol Phys 1993;27(2):241-50.
40. Overgaard J, Sand Hansen H, Overgaard M, et al. A randomized double-blind phase III study of nimorazole as hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma: Results of the Danish Head and Neck Cancer Study (DAHANCA) protocol 5-85. Radiother Oncol 1998;46:135-46.
41. Peters LJ, Rischin D, Hicks RJ, et al. Extraordinary tumor control in phase I trial of concurrent tirapazamine cisplatin and radiotherapy for far advanced head and neck cancer [abstract]. Int J Radiat Oncol Biol Phys 1998;45(Suppl):148-9.
42. Trott KR. The mechanisms of acceleration of repopulation in squamous epithelia during daily irradiation. Acta Oncol 1999;38(2):153-7.
43. Liebmann J, Cook JA, Fisher J, et al. Changes in radiation survival curve parameters in human tumor and rodent cells exposed to paclitaxel (Taxol). Int J Radiat Oncol Biol Phys 1994;29(3):559-64.
44. Haffty BG. Concurrent chemoradiation in the treatment of head and neck cancer. Hematol Oncol Clin North Am 1999;13:719-42.
45. Vokes EE, Haraf DJ, Kies MS. The use of concurrent chemotherapy and radiotherapy for locoregionally advanced head and neck cancer. Semin Oncol 2000;27:34-8.
46. Trotti A. Toxicity in head and neck cancer: A review of trends and issues. Int J Radiat Oncol Biol Phys 2000;47:1-2.
47. Forastiere AA, Berkey B, Moshe M, et al. Phase III trial to preserve the larynx: Induction chemotherapy and radiotherapy versus concomitant chemoradiotherapy versus radiotherapy alone, Intergroup Trial R91-11 [abstract]. Proceedings of the American Society of Clinical Oncology 2001;20:2a.
48. Wendt TG, Gerhard G, Grabenbauer CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: A randomized multicenter study. J Clin Oncol 1998;16:1318-24.
49. Jeremic B, Shibamoto Y, Milicic B, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: A prospective randomized trial. J Clin Oncol 2000;18:1458-64.
50. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338:1798-804.
51. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999;91:2081-6.
52. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with resectable squamous cell head and neck cancer, J Clin Oncol, in press.
53. Adelstein DJ, Lavertu P, Saxton JP, et al. Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer 2000;88:876-83.
54. Stefani S, Eells RW, Abbate J. Hydroxyurea and radiotherapy in head and neck cancer. Results of a prospective controlled study in 126 patients. Radiology 1971;101:391-6.
55. Hussey DH, Abrams JP. Combined therapy in advanced head and neck cancer: Hydroxyurea and radiotherapy. Prog Clin Cancer 1975;6:79-86.
56. Eschwege F, Sancho-Garnier H, Gerard JP, et al. Ten-year results of randomized trial comparing radiotherapy and concomitant bleomycin to radiotherapy alone in epidermoid carcinomas of the oropharynx: Experience of the European Organization for Research and Treatment of Cancer. J Natl Cancer Inst Monogr 1988;6:275-8.
57. Vermund H, Kaalhus O, Winther F, et al. Bleomycin and radiation therapy in squamous cell carcinoma of the upper aero-digestive tract: A phase III clinical trial. Int J Radiat Oncol Biol Phys 1985;11:1877-86.
58. Olver IN, Hughes PG, Smith JG, et al. Concurrent radiotherapy and continuous ambulatory infusion 5-fluorouracil in advanced head and neck cancer. Eur J Cancer 1996;32A:249-54.
59. Browman GP, Cripps C, Hodson DI, et al. Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. J Clin Oncol 1994;12:2648-53.
60. Sanchiz F, Milla A, Torner J, et al. Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys 1990;19:1347-50.
61. Marcial VA, Pajak TF, Mohiuddin M, et al. Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck. Long-term results of the Radiation Therapy Oncology Group study 81-17. Cancer 1990; 66:1861-8.
62. Al-Sarraf M, Pajak TF, Marcial VA, et al. Concurrent radiotherapy and chemotherapy with cisplatin in inoperable squamous cell carcinoma of the head and neck. Cancer 1987; 59:259-65.
63. Adelstein DJ, Kalish LA, Adams GL, et al. Concurrent radiation therapy and chemotherapy for locally unresectable squamous cell head and neck cancer: an Eastern Cooperative Oncology Group pilot study. J Clin Oncol 1993;11:2136-42.
64. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999;82:241-50.
65. Dassonville O, Formento JL, Francoual M, et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993;11:1873-8.
66. Grandis JR, Melhem MF, Gooding WE, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90:824-32.
67. Xia W, Lau YK, Zhang HZ, et al. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 1999;5:4164-74.
68. Grandis JR, Chakraborty A, Zeng Q, et al. Downmodulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. J Cell Biochem 1998;69:55-62.
69. Modjtahedi H, Affleck K, Stubberfield C, et al. EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5. Int J Oncol 1998;13:335-42.
70. Bonner JA, Raisch KP, Trummell HQ, et al. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol 2000;18:47S-53S.
71. Brown D, Wang R, Russell P. Antiepidermal growth factor receptor antibodies augment cytotoxicity of chemotherapeutic agents on squamous cell carcinoma cell lines. Otolaryngol Head Neck Surg 2000;122:75-83.
72. Lei W, Mayotte JE, Levitt ML, et al, Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells. Anticancer Res 1999;19:221-8.
73. Gieseg MA, de Bock C, Ferguson LR, Denny WA. Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033. Anticancer Drugs 2001;12:683-90.
74. Dirotnak FM, Zakowski MF, Miller VA, et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000;6:4885-92.
75. Harari PM, Huang SM. Head and neck cancer as a clinical model for molecular targeting of therapy: Combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 2001;49(2):427-33.
76. Shin DM, Donato NJ, Perez-Soler R, et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 2001;7:1204-13.
77. Hong WK, Arquette M, Nabell L, et al. Efficacy and safety of the anti-epidermal growth factor antibody (EGFR) IMC-C225, in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy [abstract]. Proceedings of the American Society of Clinical Oncology 2001;20:224a.
78. Robert F, Ezekiel MP, Spencer SA, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19:3234-43.
79. Berlanieri S, Brizel D, Scher R, et al. Pilot study of positron emission tomography in patients with advanced head and neck cancer receiving radiotherapy and chemotherapy. Head Neck 1994;16:340-6.
80. Greven K, Williams D, Keyes J, et al. Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation. Cancer 1994;74:1355-9.
81. 18F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol 2002;20:1398-404.